Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kamada Ltd (KMDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 234,733
  • Shares Outstanding, K 40,263
  • Annual Sales, $ 114,470 K
  • Annual Income, $ 22,300 K
  • 60-Month Beta 1.18
  • Price/Sales 2.07
  • Price/Cash Flow 9.11
  • Price/Book 2.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.04
  • Number of Estimates 2
  • High Estimate 0.08
  • Low Estimate 0.01
  • Prior Year 0.03
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.65 +3.19%
on 03/18/19
6.43 -9.33%
on 02/25/19
-0.19 (-3.16%)
since 02/22/19
3-Month
4.70 +24.04%
on 12/26/18
6.43 -9.33%
on 02/25/19
+0.95 (+19.47%)
since 12/21/18
52-Week
4.35 +34.02%
on 04/02/18
6.45 -9.61%
on 09/25/18
+0.98 (+20.21%)
since 03/22/18

Most Recent Stories

More News
Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?

Is (KMDA) Outperforming Other Medical Stocks This Year?

KMDA : 5.83 (-0.85%)
PhaseBio Stock Up on Positive Data From PB2452 Phase I Study

PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.

CELG : 88.15 (-1.65%)
AZN : 42.59 (-0.84%)
KMDA : 5.83 (-0.85%)
PHAS : 6.75 (+8.17%)
Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study

Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.

LXRX : 6.20 (-21.91%)
CELG : 88.15 (-1.65%)
KMDA : 5.83 (-0.85%)
SNY : 44.26 (-2.58%)
Kamada Awarded the Israeli Outstanding Exporter Award for 2017

Company received the award from the Israeli Minister of Economy and Industry for its growing export revenues

KMDA : 5.83 (-0.85%)
Zacks.com featured expert Kevin Matras highlights: Kamada, Plantronics, SkyWest, Middlefield and Walker & Dunlop

Zacks.com featured expert Kevin Matras highlights: Kamada, Plantronics, SkyWest, Middlefield and Walker & Dunlop

SKYW : 51.60 (-2.66%)
MBCN : 42.00 (unch)
PLT : 47.43 (-7.65%)
KMDA : 5.83 (-0.85%)
WD : 50.30 (-2.20%)
Scoop Up Big Gains With 5 Stocks Enjoying Rising Cash Flows

Cash is the lifeblood of any business. It offers strength, vitality and flexibility to make investment decisions, and the fuel to run the growth engine.

SKYW : 51.60 (-2.66%)
MBCN : 42.00 (unch)
PLT : 47.43 (-7.65%)
KMDA : 5.83 (-0.85%)
WD : 50.30 (-2.20%)
Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4

Achillion (ACHN) encourages with narrower-than-expected loss in Q4. However, the company did not generate any revenues in the period.

CELG : 88.15 (-1.65%)
CGEN : 3.63 (-1.63%)
ACHN : 2.93 (-6.39%)
KMDA : 5.83 (-0.85%)
Grab These 6 Stocks That Boast Substantial Net Profit Margin

Here are six stocks with spectacular net profit margin that can contribute to making a winning portfolio.

SKYW : 51.60 (-2.66%)
SCVL : 30.74 (-3.27%)
III : 3.73 (+3.04%)
SNX : 91.36 (-5.30%)
KMDA : 5.83 (-0.85%)
SP : 32.76 (-1.56%)
Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4

Merrimack's (MACK) loss betters estimates in Q4. However, the company fails to earn any revenues in the period.

CELG : 88.15 (-1.65%)
CGEN : 3.63 (-1.63%)
KMDA : 5.83 (-0.85%)
MACK : 6.69 (-6.30%)
Kamada Files Annual Report for the Year Ended December 31, 2018

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S....

KMDA : 5.83 (-0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade KMDA with:

Business Summary

Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona,...

See More

Key Turning Points

2nd Resistance Point 6.01
1st Resistance Point 5.92
Last Price 5.83
1st Support Level 5.74
2nd Support Level 5.65

See More

52-Week High 6.45
Last Price 5.83
Fibonacci 61.8% 5.65
Fibonacci 50% 5.40
Fibonacci 38.2% 5.15
52-Week Low 4.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar